Kennedy Capital Management’s BioAtla BCAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-628
Closed -$108K 701
2024
Q1
$108K Buy
628
+38
+6% +$4.72K ﹤0.01% 717
2023
Q4
$72.6K Sell
590
-5
-0.8% -$433 ﹤0.01% 682
2023
Q3
$50.6K Buy
595
+14
+2% +$1.78K ﹤0.01% 670
2023
Q2
$87.2K Buy
+581
New +$99.9K ﹤0.01% 662

Other funds holding BCAB

Kennedy Capital Management's BCAB Position: Q2 2024 in Review

Kennedy Capital Management sold out of BioAtla (BCAB) in Q2 2024, closing a stake of 628 shares — an estimated $108K sold.

Kennedy Capital Management first reported a position in BCAB in Q2 2023 and held it in 4 quarters. The position peaked at $108K in Q1 2024. 80 funds tracked by Wall St. Rank hold BCAB as of Q2 2024.

  • Kennedy Capital Management reported no remaining BioAtla position as of Q2 2024 after selling out during the quarter.
  • Kennedy Capital Management sold 628 BioAtla shares in Q2 2024, an estimated $108K.
  • Kennedy Capital Management first reported a position in BioAtla in Q2 2023 and held it in 4 quarters.
  • Kennedy Capital Management's BioAtla position peaked at $108K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held BioAtla as of Q2 2024.

Based on Kennedy Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.